- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/04 - AnorexiantsAntiobesity agents
Patent holdings for IPC class A61P 3/04
Total number of patents in this class: 7021
10-year publication summary
|
244
|
224
|
337
|
437
|
443
|
556
|
536
|
521
|
518
|
357
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2709 |
85 |
| Shionogi & Co., Ltd. | 853 |
72 |
| Novo Nordisk A/S | 2284 |
68 |
| Eli Lilly and Company | 3844 |
59 |
| Pfizer Inc. | 3381 |
56 |
| Boehringer Ingelheim International GmbH | 4648 |
54 |
| LG Chem, Ltd. | 17638 |
48 |
| Daiichi Sankyo Company, Limited | 1874 |
47 |
| Société des Produits Nestlé S.A. | 9286 |
46 |
| Janssen Pharmaceutica N.V. | 3383 |
45 |
| Nestec S.A. | 2664 |
42 |
| Taisho Pharmaceutical Co., Ltd. | 870 |
40 |
| Novartis AG | 10850 |
39 |
| AstraZeneca AB | 2908 |
38 |
| Ajinomoto Co., Inc. | 2293 |
36 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 827 |
36 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
36 |
| The Regents of the University of California | 19929 |
35 |
| F. Hoffmann-La Roche AG | 7921 |
32 |
| Bristol-myers Squibb Company | 4893 |
31 |
| Other owners | 6076 |